m+Medelevator.RU
← Поиск публикаций
Probiotics and antimicrobial proteins · 2025

Discovery and Characterization of a Novel Bacteriocin PFS-3 Targeting Multidrug-Resistant Escherichia coli.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhang Haipeng, Zhao Xiaoou, Wang Xiaoyu, Wang Xinyue, Gu Jinyang, Liu Zhongliang, Kong Lingcong, Chen Jingrui, Ma Hongxia

Аннотация

The widespread use of commercial antibiotics has led to the emergence of multidrug resistance in pathogenic bacteria, posing a significant threat to human health and underscoring the urgent need for alternative antimicrobial agents. In this study, a bacteriocin-producing strain, Bacillus velezensis FS-3 (B. velezensis FS-3), was isolated from soil in Changbaishan, China. Fermentation conditions were optimized to enhance both bacteriocin activity and yield. A novel bacteriocin, PFS-3, was purified from B. velezensis FS-3 using hydrochloric acid precipitation, organic solvent extraction, and preparative reversed-phase high-performance liquid chromatography. Liquid chromatography-mass spectrometry/mass spectrometry analysis determined its molecular weight to be 929.16 Da, and amino acid sequencing of this peptide revealed eight amino acids (STYLFEGL). To date, the biological properties of PFS-3 have not been reported. We demonstrate here that PFS-3 exhibits low toxicity and remarkable stability under diverse conditions, including variations in temperature, pH, and the presence of metal ions or organic reagents. PFS-3 displayed broad-spectrum antimicrobial activity, with particularly strong activity against Gram-negative bacteria. Notably, its minimum inhibitory concentration against multidrug-resistant Escherichia coli B2 (MDR E. coli B2) was 16 μg/mL. Mechanistic investigations revealed that bacteriocin PFS-3 exerts bactericidal effects on MDR E. coli B2 by disrupting cardiolipin in the outer membrane of the cells. Furthermore, in vivo experiments demonstrated that PFS-3 significantly improved survival rates in infection models of MDR E. coli. In conclusion, PFS-3 is a newly identified bacteriocin with strong antibacterial activity, high stability, safety, and a favorable therapeutic index, highlighting its potential applications in the food industry and biopharmaceuticals for combating MDR E. coli infections.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты